Boehringer Ingelheim collaboration for treatment of schizophrenia

Saniona and Boehringer Ingelheim GmbH (“Boehringer Ingelheim”) have an ongoing partnership for the discovery and development of new small molecule therapeutics for schizophrenia. The research and development collaboration with Boehringer Ingelheim was initiated in March 2020. The objective is to identify new treatment options for schizophrenia, by exploring a novel undisclosed CNS ion channel target using Saniona’s ion channel drug discovery platform. Boehringer Ingelheim has exclusive worldwide rights to research, develop, manufacture and commercialize therapeutics identified through the collaboration. Saniona may receive up to €76.5 million in milestone payments as well as royalties on worldwide net sales of resulting products. In addition, Saniona will receive research funding during the joint research period. 

Boehringer Ingelheim, founded in 1885, is one of the world’s 20 leading pharmaceutical companies. The focus of the family-owned company is on researching, developing, manufacturing and marketing new medications of high therapeutic value for human and veterinary medicine.